tirzepatide europe approval Lilly Receives European Marketing Authorization for in KwikPen® Presentation for Two Indications Weight-loss jab rejected for NHS

The bigger issue that has become increasingly apparent to Poison Control Centers as well as Novo Nordisk, is the presence of compounded versions of semaglutide products being sold on the market

Weight maintenance is individualized: some patients stop, some cycle back on, and others stay on a lower maintenance dose

ED50 levels for GH release in animal and in vitro studies are much lower than for non-selective secretagogues

4 Current therapeutic landscape and unmet need While resmetirom (a THR- agonist) has recently gained FDA approval for the treatment of MASH (in patients with fibrosis F2-F3), marking the first-ever pharmacological agent for this condition (Liu et al., 2025), there remains no single FDA-approved drug that effectively prevents or reverses the progression of advanced SLD to HCC